Department of Pathology, University of Chicago, Chicago, IL 60637, USA.
Trends Immunol. 2016 Jun;37(6):349-351. doi: 10.1016/j.it.2016.04.008. Epub 2016 May 8.
The overall mutational burden of a tumor is considered to be a predictive marker for the success of checkpoint blockade therapy. A recent study by McGranahan et al. reframes this notion by showing that clonal expression of neoantigens by tumor cells, rather than overall mutational burden, determines the response to checkpoint blockade therapy.
肿瘤的总体突变负担被认为是预测检查点阻断治疗成功的标志物。最近，McGranahan 等人的一项研究通过表明肿瘤细胞的新抗原的克隆表达，而不是总体突变负担，决定了对检查点阻断治疗的反应，从而重新定义了这一概念。
